For personal use only

G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement 31 July 2020

Quarterly activities report: Significant operational and regulatory progress achieved

- **Significant progress made post quarter end to scale up Independent Diagnostic Testing Facility (IDTF) business with 17 US university hospitals**
- **Key regulatory approvals for Prizma included US FDA OTC and Taiwan FDA**
- **Patch granted US FDA EUA and TGA approval in Australia**
- **Successful registration of Prizma device with Italy's Ministry of Health allowed for maiden purchase order from in-country distribution partner**
- **Two US distribution agreements allow GMV to broaden its foothold across the country**
- **Agreement with HSC Technology Group Limited (ASX: HSC) provides sales channel in Australia and NZ**

Mobile and telehealth company **G Medical Innovations (ASX: GMV) ("G Medical" or the "Company")** is pleased to provide this update for shareholders for the quarter ended 30 June 2020 (Q2 2020). G Medical achieved a number of operational and corporate milestones which position the Company for rapid growth.

Corporate:
Receipts from customers were US$985,000 – a decrease on the previous quarter (Q1 2020: US$1,232,000) and due primarily to a sudden and significant drop in patient numbers being monitored through IDTF operations in April given their inability to be fitted with monitoring devices because of a complete lockdown in the US in that month as a result of COVID-19.

Following the development of new protocols in April, G Medical is now witnessing an increase in patients using the IDTF services. This is reflected in patient monitoring numbers tracking back up in May, June and now July ***(see table 1).*** The Company expects this upward trend to continue.

Subsequent to the end of the period, in an effort to expand the Company's IDTF and remote patient monitoring services, G Medical secured six institutional deployments with leading university hospitals in the USA. Pleasingly, another 11 groups having completed evaluation and will commence deployment of the services during Q3.

July has allowed for an additional ~275 new patient enrolments from the two new hospitals deploying the service (refer ASX announcement: 27 July 2020), which is over and above the initial ~2,000 deployments received from the first four university hospitals implementing the IDTF platform (refer ASX announcement: 16 July 2020).




Table 1: *Patients monitored through IDTF services on a monthly basis (January 2020 – July 2020)*

Management commentary

CEO Dr Yacov Geva said: *"This was an exceptionally good quarter for G Medical and we have made considerable progress despite the challenges posed by the macroeconomic environment. The slight drop in customer receipts was anticipated but our focus is now very much on broadening revenue streams and locking in a greater baseload of recurring revenue. The initiatives undertaken in the quarter and July reflect this focus.*

"Subsequent to the end of the quarter, we were pleased to report on the significant growth of our IDTF business as a result of university hospitals deploying this very dependable and well-accepted service. This is a major development for G Medical and it is a key catalyst for the Company to establish larger, stable recurring revenue streams. Remote patient monitoring is now a rapidly growing sector and it presents us with a big opportunity.

"Also noteworthy is the sales channel we have established for the Prizma in Italy with Meditel, and the key regulatory approvals secured. The Company is in a very strong position and poised for growth. We are expecting another quarter of growth and I look forward to reporting on key developments to shareholders."

Summary of corporate and operations progress for the quarter

FDA grants Over-the-Counter (OTC) Authorisation in the USA:
Further strengthening the Company's regulatory approval position, G Medical received OTC approval (also referred to as non-prescription designation) for its Prizma device from the US Food & Drug Administration. This builds on the Prizma's existing FDA 510(K) Class II medical device approval, granted in September 2017.

Authorisation followed discussions with the FDA upon the release of a guidance document issued by the organisation in response to the COVID-19 pandemic. Following the release of the document, G Medical contacted the FDA directly to seek acknowledgement that the Prizma satisfied the scope of authorisation defined as a 'non-invasive remote monitoring devices that measure or detect common physiological parameters and that are used to support patient monitoring during the COVID-19 public health emergency'[i].

The FDA subsequently confirmed that the Prizma satisfied the guidance documents scope and expanded the use of the device from prescription to OTC. The change in classification allows for the device to be sold directly to consumers, without a prescription.

OTC approval for the Prizma allows G Medical to target the US market more aggressively. The Company continues to work with a number of distribution partners across the USA to expedite device uptake.

For personal use only

Patch granted 'Emergency Use Authorisation' from US FDA for patients being treated for COVID-19:
In a significant milestone, G Medical received Emergency Use Authorisation ("EUA") status from the US FDA for the Company's Vital Signs Monitoring System ("VSMS") ECG Patch ("Patch") for the remote monitoring of the QT interval of an ECG in patients who are undergoing treatment in a hospital setting for COVID-19 with drugs that can prolong QT intervals and may cause fatal arrhythmias.

Prolonged QT intervals outline a rhythm disorder in the heart (medically known as an arrhythmia) whereby an individual's heart muscle takes longer to recharge between beats. This can potentially lead to fainting, seizures or sudden death.

Under the EUA 'Issuance of Authorisation', the FDA concluded that "there is no adequate, approved, and available alternative to the emergency use of the VSMS Patch for remote monitoring of the QT interval of an ECG in patients who are undergoing treatment in a hospital setting for COVID-19 with drugs that can prolong QT intervals and may cause life-threatening arrhythmias. In addition, remote monitoring may reduce the [Health Care Professionals] HCP risk of exposure to SARS-CoV-2 during the COVID-19 pandemic."[ii]

The Authorisation will be effective until the declaration that circumstances exist justifying the authorisation is terminated under section 564(b)(2) of the relevant Act or the EUA is revoked under section 564(g) of the Act.

Manufacturing of the Patch is ongoing at G Medical's wholly owned R&D facilities in Israel and also via and FDA and ISO certified medical device contract manufacturer in the country. Manufacturing in Israel will continue and subsequently move to G Medical's Guangzhou China production facility in the future.

G Medical Extended Holter Patch (GMP) granted TGA approval:
Marking a significant milestone, the Company was granted approval from the Therapeutic Goods Administration for its Extended Holter Patch. Upon receipt of approval, the GMP now officially complies with all relevant Australian medical and safety requirements as a Class IIa medical device.

This development will assist the Company in its entry into the Australian market, as the GMP can now be used in collaboration with the deployment of its IDTF type services through its agreement with HSC Technology Group.

Successful registration of Prizma device in Italy and maiden purchase order:
G Medical entered into the Italian market, following the successful registration of its Prizma device with the Italian Health Ministry's database of medical products (registration number: RDM 19138127).

Successful registration allowed the Company to progress its distribution agreement with leading European telemedicine provider Meditel srl ("Meditel") (www.meditelitalia.it) to promote and sell the Prizma device and Extended Holter in Italy.

Shortly after the completion of the registration process, G Medical secured its maiden purchase order from Meditel for an initial 1,000 Prizma devices. A considerable amount of work was undertaken to ensure the Prizma device was ready for sale in Italy, including the translation of all relevant smartphone apps associated with the device; translating and printing relevant packaging; provision of documentation to respective regulatory bodies in Italy; ongoing education initiatives with Meditel personnel; and ensuring contract manufacturers and logistics providers have product at the ready to fulfil consumer orders.

The first batch of Prizma units has been delivered to Meditel and as such Meditel is processing customer sales through its online store. As well as direct-to-consumer sales, Meditel and GMV are building commercial sales channels targeting physicians, healthcare professionals and medical organisations. Meditel has an active marketing and business development program to underpin sales.

For personal use only

The Company is confident that it will receive repeat orders from Meditel over the coming quarters. G Medical will continue to work with Meditel to integrate its devices into the Meditel's 'Lifechart' platform, which is used for home monitoring of chronic patients. The web-based platform is certified to deliver electrocardiogram (ECG) monitoring services and provides another revenue generating channel for G Medical.

Distribution agreement with remote patient solutions company LiveCare:
To bolster operations in the USA, G Medical entered into a three-year non-exclusive distribution agreement with LiveCare Corp. ("LiveCare") (www.livecareusa.com), under which LiveCare will promote the sale and distribute the Prizma device in the USA. To complement the Company's Independent Diagnostics Testing Facilities (IDTF) platform, GMV will work with LiveCare to integrate the Prizma into the Link+ platform, which will be offered directly to US consumers.

Life+ 4G Smart Home Gateway that integrates an array of medical devices into a patient's home using a simple, touch-free syncing process. The Link+ helps monitor chronic care patients, offers better patient outcomes, reduces healthcare costs and lowers readmission rates.

Once a patient uses the home monitoring service or a connected device, all data is transmitted through the Link+ directly to the FDA cleared, LiveCare HIPAA cloud. If there is a decline in the patient's condition, the system will automatically generate an alert to a call centre, which can be escalated as required.

LiveCare has an established footprint in the US and is the preferred provider to the Independent Physician Association of America (TIPAAA), the leading trade association serving independent and integrated physician associations. TIPAAA currently represents approximately 700 organisation and affiliates in 39 states and more than 300,000 physicians.

Distribution agreement with All County Health Care Inc. to broaden US footprint:
Further expanding exposure in the US market, G Medical secured a distribution agreement with Medicare-certified, home health company All County Health Inc. (www.allcountryhealthcare.com) to promote and distribute the Prizma device in the USA.

All County is a large, privately held company located in Lauderdale Lake, Florida. It specialises in the provision of quality home-based healthcare services through the dispatch of medical professionals to patient's homes following a referral.

The group has a network of over 1,400 physicians throughout South Florida and regularly engages with hospitals and medical organisations in the region. The Company is confident that All County can leverage its network to expedite device uptake with patients and physicians.

Agreement with HSC Technology Group to expand into Australia and New Zealand:
G Medical executed a non-exclusive distribution agreement with HSC Technology Group Limited (ASX: HSC) (formerly HomeStay Care Limited) for the distribution of its Prizma device in Australia and New Zealand. Further, both parties will work together to integrate the device into HSC's IoT platform to provide remote vital signs monitoring capabilities via HSC's uVue telehealth platform ("uVue") and a 24-hour monitoring response to users in Australia and New Zealand.

Following integration, the Prizma device will be made available primarily using the uVue platform as the communication delivery system. uVue is a cloud-based system telehealth platform that is connected to a client's television. It is used by a large number of aged care providers that have challenges communicating effectively with the elderly due to the technology gap experienced by seniors.

For personal use only

Subsequent to the end of the quarter, G Medical and HSC broadened the agreement to offer G Medical's IDTF type infrastructure and remote patient monitoring solutions in Australia and New Zealand. The expanded offering will deliver a more comprehensive service that can be utilised by hospitals, health insurance companies and other healthcare providers for transitional care programs, allowing patients to return home earlier by using 24-hour remote patient monitoring.

Patients enrolled under the service will be charged a subscription fee ranging from ~$A19-$35 per month, which will be shared between G Medical, HSC Technology Group and third-party providers. Further, the establishment will help G Medical cement its footprint in Australia and New Zealand and unlock another sales channel for its TGA-approved Prizma and Patch devices.

Fosun Hani Securities Limited and Boustead Securities engaged to lead NASDAQ IPO:
G Medical engaged Fosun HanI Securities Limited ("Fosun Hani) and Boustead Securities, LLC ("Boustead") as Joint Financial and Listing Advisors to the Company's planned initial public offering ("IPO") on the NASDAQ stock exchange ("NASDAQ").

Fosun Hani is a wholly owned subsidiary of Fosun International Limited (HKEx: 00656) ("Fosun Group"), a leading global investment group. Fosun Hani is based in Hong Kong and acts as Fosun Group's integrated financial hub and primary investment arm. Established in 1987, it has a strong track record across a broad range of sectors and is a participant member of The Stock Exchange of Hong Kong Limited.

Boustead is a California based investment banking firm that specialises in IPOs, M&A, capital raises and restructuring assignments in a wide array of industries and geographies. Its core value proposition is to create opportunity through innovative solutions and tenacious execution. Boustead has an experienced management team in the United States and has considerable experience with NASDAQ related transactions.

The engagement with both parties also contemplates:

1. Them acting in the capacity of underwriters, subject to the finalisation of the IPO offer price and quantum of the associated capital raising and the execution of a formal underwriting agreement; and
2. The parties targeting effecting the NASDAQ listing in Q3 CY2020.

Both parties will be instrumental as G Medical explores the opportunity of listing of the NASDAQ. The listing process remains ongoing and the Company will provide further updates to shareholders when applicable.

Sponsorship agreement with the Royal Australian College of General Practitioners (RACGP):
The Company entered into a sponsorship arrangement with one of Australia's largest professional general practice organisation, the RACGP to assist with the groups Members' Digital Care Pack Campaign. Under the agreement, the Prizma device, G Medical telehealth app, and patient and physician portals will be offered to members at special rates.

RACGP represents over 40,000 members in urban and rural areas across Australia. The group aims to support GPs, general practice registrars and medical students through education, training and research and supplies ongoing professional development activities, resources and educational material.

Completion of oversubscribed capital raise:
G Medical completed an oversubscribed placement following the issue of 85,528,236 fully paid ordinary shares to professional, sophisticated and institutional investors to raise $6m. Funds from the placement were used to repay MEF, I L.P. ("Magna") (refer ASX announcements dated 11 February 2020 and 7 April 2020), a portion of loan funds owing to Dr Yacov Geva, working capital purposes and costs associated with the placement.

For personal use only

Permit licence for Prizma secured from Taiwan Food and Drug Administration (FDA):
G Medical received a permit licence for the sale and use of the Prizma device in Taiwan. The permit licence was received through G Medical's partner First Channel Ltd ("FCL") and granted by the Taiwan FDA following the provision of ancillary product information.

G Medical continues to work with FCL to delineate commercial strategies for the Taiwanese market. The commencement of the two parties distribution agreement remains subject to FCL finalising and entering into additional definitive agreements with third parties. To expedite market entry, G Medical is also exploring other partnerships within Taiwan.

Ends

Approved for release by Yacov Geva, Managing Director

For more information, please contact:

Brendan De Kauwe
Director
Brendan@gmedinnovations.com

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 (0) 431 271 538

About G Medical Innovations
G Medical **(ASX: GMV)** was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:
G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.

[i] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring-during

[ii] https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations-medical-devices

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

For personal use only

Name of entity

G Medical Innovations Holdings Ltd

ABN	**Quarter ended ("current quarter")**
617 204 743	30 June 2020

Consolidated statement of cash flows		**Current quarter $US'000**	**Year to date (6 months) $US'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	985	2,217
1.2	Payments for		
	(a) research and development	(109)	(171)
	(b) product manufacturing and operating costs	(389)	(727)
	(c) advertising and marketing	(85)	(130)
	(d) leased assets	-	-
	(e) staff costs	(1,386)	(2,618)
	(f) administration and corporate costs	(1,185)	(1,421)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	6	6
1.5	Interest and other costs of finance paid	(32)	(44)
1.6	Income taxes paid		
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	111	139
1.9	**Net cash from / (used in) operating activities**	(**2,084**)	(**2,749**)

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(170)	(177)
	(d) investments	-	-
	(e) intellectual property	-	-

+ See chapter 19 of the ASX Listing Rules for defined terms.

Consolidated statement of cash flows		Current quarter $US'000	Year to date (6 months) $US'000
	(f) other non-current assets	-	(30)
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	44	82
2.6	**Net cash from / (used in) investing activities**	**(126)**	**(125)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,942	5,787
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(206)	-
3.5	Proceeds from borrowings	1,950	1,841
3.6	Repayment of borrowings	(4,118)	(4,118)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**2,568**	**3,510**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	185	(93)
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,084)	(2,749)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(126)	(125)

For personal use only

Consolidated statement of cash flows		Current quarter $US'000	Year to date (6 months) $US'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,568	3,510
4.5	Effect of movement in exchange rates on cash held		
4.6	**Cash and cash equivalents at end of period**	543	543

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $US'000	Previous quarter $US'000
5.1	Bank balances	543	185
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**543**	**185**

6.	Payments to related parties of the entity and their associates	Current quarter $US'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

For personal use only

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $US'000**	**Amount drawn at quarter end $US'000**
7.1	Loan facilities	3,096	3,096
7.2	Credit standby arrangements		
7.3	Other – Loans from controlling shareholder	2,162	2,162
	Other – Funding facility	(*) 20,569	841
7.4	**Total financing facilities**	25,827	6,099
	(*) A$ 30,000,000		
7.5	**Unused financing facilities available at quarter end**		19,728
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

For personal use only

For personal use only

7.1- The Company received several loans from Bank Mizrahi Tfahot in Israel. As of June 30, 2020, the total amount of these loans is: US$ 0.994 M.

The loans are denominated in US Dollars and NIS and bear interest rates of Libor + (2.5%) and prime+ (0.5%- 0.85%) per annum.

The Company's major shareholder provides a guarantee for part of these loans payments.

Upon CardioStaff acquisition, additional long- term loans were added to the Company balance.

As of December 31, 2019, the total amount of these loans is US$ 1.226 M and include mainly loans from private people/institutions and bear interest of 4%-12% per annum.

PPP loan:

In April 2020, under the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") in United States the Company subsidiary in the USA signed an agreement to receive a long-term loan ("PPP loan") at amount of $873,487 from Bank Of America.

According to the terms of the loan, the payments will be deferred for six months from the funding date and no collateral or personal guarantees are required, the loan have a maturity of two years and an interest rate of 1%.

7.3- Loans from controlling shareholder (Yacov Geva) - Yacov Geva has entered into a credit line agreement in May 2018, to provide the Company up to US$ 3 M. The agreement was amended and effective as of October 1, 2018 the aggregate amount available to the company is US$ 10 M.

On April 24, 2019 our shareholders approved the conversion of approx. US$ 3.3 million that had been drown from the 2016 and 2018 credit line into an aggregate of 14,706,719 shares.

On June 24, 2019 our shareholders approved additional conversation of US$ 2 M that had been drown from the 2018 credit line into an aggregate of 14,532,771 shares.

On March 19, 2020 our shareholders approved additional conversation of US$ 5.0 million that had been drown from the credit line into 93,339,307 shares.

As of June 30, 2020, the amount drawn of Yacov Geva loans totalled at US$ 2.162 M.

Funding facility -

The company has secured capital commitments of up to A$30 million (~ US$ 20 million) over a three year period from Luxembourg based GEM Global Yield LLC SCS .

Subject to the terms of a Capital Commitment Agreement, the Company may choose to, on one or more occasions within the three year period, subject to conditions precedent draw down on the facility by giving GEM 15 trading days' notice to subscribe for fully paid ordinary shares in the Company. The number of shares which GMV may draw down under a notice is capped at 1,000% of the average daily number of GMV shares traded on ASX during the 15 trading days prior to that draw down notice, subject to adjustments.

If the Company issues a draw down notice, the subscription price of the shares to be issued to GEM (or its nominees) will be 90% of the higher of:

- the average closing bid price of GMV shares as quoted by ASX over the pricing period, being the 15 consecutive trading days after GMV gives the draw down notice to GEM (subject to certain adjustments); or
- a fixed floor price nominated by the Company in its draw down notice.

For personal use only

8.	Estimated cash available for future operating activities	$US'000
8.1	Net cash from / (used in) operating activities (Item 1.9)	(2,084)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	543
8.3	Unused finance facilities available at quarter end (Item 7.5)	19,728
8.4	Total available funding (Item 8.2 + Item 8.3)	20,271
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	9.72

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

July 31, 2020

Date: .....

Yacov Geva

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only